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ABSTRACT
Objective: We aimed to assess the effects of age, comorbidity,
and disease-speciﬁc functions on utility scores derived from
three methods on prostate cancer.
Methods: A total of 330 Japanese prostate cancer patients
were asked to answer self-administered questionnaires.
Community-weighted utility scores were derived from the
EuroQoL-5D (EQ-5D) and the Short Form-36 (SF-36), while
the patient’s directly elicited utility score was derived from
time trade-off technique. Univariate and multivariate analy-
ses were performed to examine the relation between covari-
ates and utility scores. We assigned age, the Index of
Co-existent Disease, and disease-speciﬁc functions including
sexual, urinary, bowel, and hormonal function as covariates.
Results: Bowel and hormonal function were related to utility
scores, while age and sexual function were not. Comorbid-
ities were more closely related to utility scores derived from
EQ-5D and SF-36.
Conclusions: These results contribute to an understanding of
which factor has an impact on utility scores in patients with
prostate cancer.
Keywords: disease-speciﬁc functions, prostatic neoplasms,
quality of life, utilities.
Introduction
Recently, early detection of clinically localized prostate
cancer has been achieved by the prevalence of prostate-
speciﬁc antigen (PSA) screening [1]. Patients newly
diagnosed have to make decisions on treatment. By
receiving any treatments, they may experience treat-
ment complications including sexual, urinary, bowel,
and hormonal dysfunctions. To enable a comparison
of treatments taking quality into consideration in addi-
tion to survival, assigning utility scores derived from
the general public or patients on each health state is
necessary. Utility scores are numbers that represent the
strength of an individual’s preference for different
health outcomes under conditions of uncertainty. We
aim to evaluate the effects of age, comorbidity, and
treatment complications on utility scores derived from
the general public or patients before conducting deci-
sion analyses for localized prostate cancer in the PSA
era.
Methods
Ethic Approval and Informed Consent
The research protocol was approved by the ethics
review committees of Juntendo University, Juntendo
Urayasu Hospital, and the International Medical
Center. All participating patients gave informed
consent to be interviewed for the study.
Participants
Between October 2004 and September 2005, prostate
cancer outpatients were recruited at these three insti-
tutions in Japan. Patients receiving radical prostatec-
tomy, external beam radiotherapy, brachytherapy,
primary hormonal therapy, watchful waiting, or a
combination of these for localized prostate cancer, and
patients with hormone refractory prostate cancer par-
ticipated in this study. Patients who had difﬁculty com-
municating verbally were excluded.
Measures
All patients were asked to answer the self-administered
questionnaires. The EuroQoL-5D (EQ-5D) [2] and the
Short Form-36 version 2.0 (SF-36) [3] were used to
assess the generic quality of life (QOL). The UCLA
Prostate Cancer Index (PCI) version 1.2 [4] which
measured sexual function, urinary function, and bowel
problem, the hormonal function domain of Expanded
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Prostate Cancer Index Composite (EPIC) [5], and the
International Prostate Symptom Score [6] which
measured lower urinary tract symptoms (LUTS), were
used to assess disease-speciﬁc QOL. Patient age and
the Index of Co-existent Disease (ICED) [7] were also
asked in the questionnaires. ICED includes two sub-
scales: 1) the severity of each set of categories of co-
existent medical conditions, the Index of Disease
Severity; and 2) the degree of physical impairment, and
the Index of Physical Impairment. The ﬁnal index is an
ordinal scale in which the two subscales are combined
to form four levels of severity. All questionnaires
except EPIC were made through the process of trans-
lation, back-translation, reﬁnement by the developer
of the original, and establishment of the modiﬁed Japa-
nese version. Because the Japanese version of EPIC
was not developed, we translated hormonal function
domain of EPIC from English to Japanese and exam-
ined its test–retest reliability in 21 Japanese patients
with prostate cancer. The weighted kappa coefﬁcient of
each item ranged from 0.41 to 0.86.
The interview of time trade-off (TTO) technique
using props was performed to directly derive utility
scores. The props were specially designed boards and a
sliding scale on the board showed the number of years
in perfect health compared to t years in the poor health
state [8].
For a current health state better than dead, a
“10-year” TTO elicits the number of years, t (<10),
where the respondent is indifferent to the following
two prospects:
• to live in full health for t years;
• to live in the current health state for 10 years.
For a state worse than dead, it elicits the value of t
(<10) where the respondent is indifferent to the two
prospects:
• to live in the current health state for t years;
• then in full health for (10-t) years;
• immediate death.
The responses thus derived need to be adjusted so
that they lie within the boundary of -1 and +1, with
0 equivalent to dead. Conventionally, this is re-
presented by h = t/10 for states better than dead, and
h = (t/10)-1 for states worse than dead, where t repre-
sents the obtained response and h represents the
adjusted TTO value [9]. This study used 10 years as
the reference duration, and 1 year as the smallest unit
of measurement.
Time trade-off technique is the scaling method most
widely used [10] because TTO using props causes few
misunderstandings and the interview can be conducted
within 5 min per person. We examined its test–retest
reliability in 21 Japanese patients with prostate cancer.
Intraclass correlation coefﬁcient was 0.83 (95% CI,
0.68–0.92).
Community-weighted utility scores were derived
from EQ-5D and SF-36. Indirectly elicited utility
scores of EQ-5D were derived from the general public
using TTO [2]. We adapted utility scores from SF-36
using the approach proposed by Brazier et al. [11].
Statistical Analyses
We assessed the relation between covariates and utility
scores on prostate cancer. Age, ICED, and disease-
speciﬁc functions were assigned as covariates. Pearson
correlation coefﬁcients were calculated to conﬁrm mul-
ticollinearity in the disease-speciﬁc functions. After
stratifying age, ICED, and disease-speciﬁc functions
into quartiles or clinical classiﬁcation, trend tests were
performed to examine the linearity between these
covariates and the utility scores. To assess these rela-
tions simultaneously, we applied the general linear
model by the least-squares means method in consider-
ation of the intrapatient correlation of utility scores.
Statistical analyses were performed with SAS software.
All statistical tests were two-sided.
Results
A total of 330 patients were recruited at three institu-
tions. Seven patients were excluded because of poor
interview quality. The remaining 323 patients were
included in this study. Mean age was 71.5 (SD 6.0)
years. Mean utility score derived from EQ-5D, SF-36,
and TTO was 0.90 (SD 0.15), 0.74 (SD 0.08), and
0.89 (SD 0.15), respectively (Table 1). In the univariate
analyses, all the variables except age and sexual func-
tion had a linear trend with TTO, EQ-5D, and SF-36
(ICED, P = 0.048, P < 0.001, and P < 0.001; urinary
function, P = 0.013, P < 0.001, and P = 0.006; bowel
problem, P < 0.001, P < 0.001, and P < 0.001; hor-
monal function, P < 0.001, P < 0.001, and P < 0.049;
LUTS, P = 0.007, P < 0.001, and P < 0.002, respec-
tively, Table 1). The absolute value of Pearson corre-
lation coefﬁcients for disease-speciﬁc function scores
ranged from 0.034 to 0.323 (Table 2), and multi-
collinearity in the disease-speciﬁc functions was not
conﬁrmed. In the multivariate analyses using general
linear model, bowel problems and hormonal function
were related to the utility scores derived from TTO,
EQ-5D, and SF-36 (bowel problems, P < 0.001,
P = 0.015, and P = 0.007; hormonal function,
P < 0.001, P < 0.001, and P = 0.075, respectively,
Table 3), while age and sexual function were not
related in TTO, EQ-5D, and SF-36 (age, P = 0.085,
P = 0.631, and P = 0.721; sexual function, P = 0.526,
P = 0.941, and P = 0.202, respectively, Table 3).
Urinary function and LUTS were only related to those
derived from EQ-5D (P = 0.005 and P < 0.001, respec-
tively, Table 3). Comorbidity was more closely related
to those derived from EQ-5D and SF-36 (P < 0.001
and P = 0.002, respectively, Table 3).
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Discussion
Evaluating the effects of disease-speciﬁc functions on
utility scores is important because the disease-control
beneﬁts of curative therapy may be offset by treatment
complications. This study also evaluates the effects
of age and comorbidity on utility scores, because little
has been published [12]. When discussing treatment
options with prostate cancer patients, the effects of
age, comorbidity, and treatment complications may be
a central point in addition to clinical stage, pretreat-
ment PSA, and Gleason score.
In three methods, although the utility scores derived
from EQ-5D showed a relation to disease-speciﬁc
Table 1 Relationship between the stratiﬁed covariates and utility scores derived from three methods
Covariates Group n
TTO EQ-5D SF-36
Utility score (SD) P Utility score (SD) P Utility score (SD) P
All patients 323 0.89 (0.15) 0.90 (0.15) 0.74 (0.08)
Age 51–59 7 0.81 (0.40) 0.182 0.77 (0.22) 0.212 0.72 (0.19) 0.958
60–69 112 0.90 (0.13) 0.92 (0.13) 0.74 (0.07)
70–79 172 0.88 (0.15) 0.91 (0.14) 0.74 (0.06)
80–89 32 0.90 (0.12) 0.85 (0.21) 0.72 (0.12)
ICED* 0 60 0.90 (0.19) 0.048 0.93 (0.14) <0.001 0.75 (0.09) <0.001
1 173 0.91 (0.12) 0.93 (0.12) 0.75 (0.06)
2 74 0.84 (0.17) 0.85 (0.15) 0.72 (0.06)
3 16 0.83 (0.21) 0.71 (0.23) 0.64 (0.14)
Sexual function† 16–85 80 0.93 (0.10) 0.163 0.93 (0.11) 0.128 0.76 (0.05) 0.016
4–16 57 0.84 (0.19) 0.90 (0.15) 0.73 (0.07)
3 35 0.89 (0.17) 0.89 (0.14) 0.72 (0.07)
0 149 0.88 (0.16) 0.90 (0.16) 0.73 (0.09)
Urinary function† 100 170 0.91 (0.12) 0.013 0.94 (0.11) <0.001 0.75 (0.07) 0.006
75–95 73 0.87 (0.18) 0.88 (0.17) 0.71 (0.10)
11–74 80 0.86 (0.18) 0.84 (0.17) 0.72 (0.09)
Bowel problem† 100 134 0.92 (0.11) <0.001 0.94 (0.12) <0.001 0.75 (0.07) <0.001
93–95 47 0.89 (0.12) 0.91 (0.15) 0.73 (0.08)
81–92 62 0.92 (0.09) 0.91 (0.13) 0.74 (0.06)
0–80 80 0.81 (0.23) 0.84 (0.18) 0.71 (0.09)
Hormonal function† 100 155 0.92 (0.10) <0.001 0.93 (0.14) <0.001 0.74 (0.08) 0.049
95 26 0.88 (0.17) 0.91 (0.12) 0.73 (0.06)
85–90 71 0.90 (0.14) 0.92 (0.12) 0.75 (0.06)
35–80 71 0.82 (0.23) 0.84 (0.17) 0.71 (0.09)
LUTS‡ 0–7 168 0.92 (0.10) 0.007 0.93 (0.12) <0.001 0.74 (0.06) 0.002
8–19 116 0.86 (0.17) 0.89 (0.16) 0.74 (0.09)
20–35 38 0.84 (0.24) 0.83 (0.19) 0.70 (0.10)
*ICED has four grades of severity from 0 (none) to 3 (severe).
†Lower scores on sexual function, urinary function, bowel problem, and hormonal function indicate higher degrees of dysfunction.
‡Lower score on LUTS indicates lower degrees of symptoms.
EQ-5D, EuroQoL-5D; ICED, Index of Co-existent Disease; LUTS, lower urinary tract symptoms; SD, standard deviation; SF-36, Short Form-36;TTO, time trade-off.
Table 2 Pearson correlation coefﬁcients between disease
speciﬁc functions*
Sexual
function
Urinary
function
Bowel
problem
Hormonal
function LUTS
Sexual function† 0.170 0.117 0.119 -0.056
Urinary function† 0.160 0.034 -0.323
Bowel problem† 0.288 -0.320
Hormonal function† -0.199
LUTS‡
*LUTS indicates lower urinary tract symptoms.
†Lower scores on sexual function, urinary function, bowel problem, and hormonal
function indicate higher degrees of dysfunction.
‡Lower score on LUTS indicate lower degrees of symptoms.
Table 3 Simultaneous analyses by least-squares means method
for the relationship between covariates and utility scores derived
from three methods
Methods Covariates Estimates Standard error P
TTO Intercept 0.3170 0.1350
Age 0.0002 0.0015 0.885
ICED -0.0036 0.0115 0.753
Sexual function 0.0003 0.0005 0.526
Urinary function 0.0005 0.0004 0.239
Bowel problem 0.0027 0.0006 <0.001
Hormonal function 0.0032 0.0008 <0.001
LUTS -0.0015 0.0013 0.254
EQ-5D Intercept 0.5651 0.1261
Age -0.0007 0.0014 0.631
ICED -0.0390 0.0108 <0.001
Sexual function 0.0000 0.0005 0.941
Urinary function 0.0012 0.0004 0.005
Bowel problem 0.0014 0.0006 0.015
Hormonal function 0.0025 0.0007 <0.001
LUTS -0.0024 0.0012 0.055
SF-36 Intercept 0.5644 0.0721
Age 0.0003 0.0008 0.721
ICED -0.0189 0.0061 0.002
Sexual function 0.0004 0.0003 0.202
Urinary function 0.0003 0.0002 0.162
Bowel problem 0.0009 0.0003 0.007
Hormonal function 0.0007 0.0004 0.074
LUTS -0.0006 0.0007 0.418
EQ-5D, EuroQoL-5D; ICED, Index of Co-existent Disease; LUTS, lower urinary tract
symptoms; SF-36, Short Form-36;TTO, time trade-off.
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function, the inﬂuences were much less than those
from comorbidities. In conducting decision analysis
using utility scores derived from EQ-5D, adjusting
with comorbidity may be required.
The utility score from SF-36 was inﬂuenced by
comorbidity, similar to EQ-5D, and was less related to
the disease-speciﬁc function.
Our results showed that bowel problem and hor-
monal function were closely related to the utility
score derived from TTO, while age and comorbidities
were not correlated. These ﬁndings suggest that
utility scores derived from Japanese men may differ
from those elicited in foreign population. In the study
of Stewart et al. [13], they reported the bowel
problem was rated as signiﬁcantly more bothersome
than impotence and urinary incontinence, and age
was reported as a signiﬁcant predictor of higher
utility ratings. Krahn et al. evaluated the disease-
speciﬁc functions with UCLA PCI and utility scores
with different methods in prostate cancer [14]. They
reported that sexual, urinary, and bowel dysfunctions
had less impact on utility scores than reported in pre-
vious studies when adjustments were made for
concomitant changes in other QOL domains. Saigal
et al. reported the utility score derived from TTO
for current sexual function decreased by 0.13 and
for current urinary function decreased by 0.09
at 6 months after undergoing treatment including
radical prostatectomy, external beam radiotherapy,
brachytherapy, or watchful waiting. [15] Neverthe-
less, they reported that the utility score for current
bowel problems showed no change between pre- and
post-treatment, despite the dropping of bowel
problem scores. The use of scores derived from Japa-
nese may be justiﬁed if cultural differences determine
large differences in utility scores. The limitation of
our study is that the comparison between the differ-
ent races was not performed.
In conclusion, bowel problem and hormonal func-
tion in the disease-speciﬁc functions might have
impact on utility scores derived from all three
methods, while age and sexual function had less
impact. Comorbidity was related to utility scores
derived from EQ-5D and SF-36. A clear understand-
ing of the effects of age, comorbidity, and treatment
complications should be gained in conducting deci-
sion analyses.
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